
James D. Anderson
Examiner (ID: 12640, Phone: (571)272-9038 , Office: P/1629 )
| Most Active Art Unit | 1629 |
| Art Unit(s) | 1614, 1629 |
| Total Applications | 1668 |
| Issued Applications | 822 |
| Pending Applications | 121 |
| Abandoned Applications | 752 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17426741
[patent_doc_number] => 20220054449
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => Combination Of Local And Systemic Therapies For Enhanced Treatment of Dermatologic Conditions
[patent_app_type] => utility
[patent_app_number] => 17/466600
[patent_app_country] => US
[patent_app_date] => 2021-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8079
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17466600
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/466600 | Combination Of Local And Systemic Therapies For Enhanced Treatment of Dermatologic Conditions | Sep 2, 2021 | Abandoned |
Array
(
[id] => 18254462
[patent_doc_number] => 20230081501
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-16
[patent_title] => RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/459179
[patent_app_country] => US
[patent_app_date] => 2021-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 98199
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17459179
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/459179 | Accelerating fibrosarcoma protein degrading compounds and associated methods of use | Aug 26, 2021 | Issued |
Array
(
[id] => 17334551
[patent_doc_number] => 20220000882
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => METHOD OF TREATING DEMENTIA
[patent_app_type] => utility
[patent_app_number] => 17/459868
[patent_app_country] => US
[patent_app_date] => 2021-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4691
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17459868
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/459868 | Method of treating dementia | Aug 26, 2021 | Issued |
Array
(
[id] => 17441796
[patent_doc_number] => 20220062301
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => BROMFENAC, PREDNISOLONE, AND MOXIFLOXACIN COMPOSITIONS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/458289
[patent_app_country] => US
[patent_app_date] => 2021-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70367
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17458289
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/458289 | Bromfenac, prednisolone, and moxifloxacin compositions and methods | Aug 25, 2021 | Issued |
Array
(
[id] => 17441766
[patent_doc_number] => 20220062271
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => LOTEPREDNOL AND MOXIFLOXACIN COMPOSITIONS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/458532
[patent_app_country] => US
[patent_app_date] => 2021-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69950
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17458532
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/458532 | Loteprednol and moxifloxacin compositions and methods | Aug 25, 2021 | Issued |
Array
(
[id] => 17718967
[patent_doc_number] => 20220211686
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => FORMULATIONS OF 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE
[patent_app_type] => utility
[patent_app_number] => 17/412187
[patent_app_country] => US
[patent_app_date] => 2021-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35313
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17412187
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/412187 | Formulations of 2-(4-chlorophenyl)-N-((2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | Aug 24, 2021 | Issued |
Array
(
[id] => 18122802
[patent_doc_number] => 20230008410
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-12
[patent_title] => LIQUID NALOXONE SPRAY
[patent_app_type] => utility
[patent_app_number] => 17/411507
[patent_app_country] => US
[patent_app_date] => 2021-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19171
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411507
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/411507 | Liquid naloxone spray | Aug 24, 2021 | Issued |
Array
(
[id] => 18707467
[patent_doc_number] => 20230330041
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => APPLICATION OF TRIS (HYDROXYMETHYL) AMINOMETHANE PHARMACEUTICALLY ACCEPTABLE SALT TO DRUGS FOR TREATING HYPERURICEMIA
[patent_app_type] => utility
[patent_app_number] => 18/043068
[patent_app_country] => US
[patent_app_date] => 2021-08-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12233
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043068
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/043068 | APPLICATION OF TRIS (HYDROXYMETHYL) AMINOMETHANE PHARMACEUTICALLY ACCEPTABLE SALT TO DRUGS FOR TREATING HYPERURICEMIA | Aug 19, 2021 | Abandoned |
Array
(
[id] => 18852672
[patent_doc_number] => 11850224
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-26
[patent_title] => Storage stable aqueous injectable solution comprising diclofenac
[patent_app_type] => utility
[patent_app_number] => 17/405292
[patent_app_country] => US
[patent_app_date] => 2021-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4318
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17405292
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/405292 | Storage stable aqueous injectable solution comprising diclofenac | Aug 17, 2021 | Issued |
Array
(
[id] => 17412688
[patent_doc_number] => 20220047592
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-17
[patent_title] => METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/400257
[patent_app_country] => US
[patent_app_date] => 2021-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7879
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400257
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/400257 | METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS | Aug 11, 2021 | Abandoned |
Array
(
[id] => 17441711
[patent_doc_number] => 20220062216
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => COMPOSITIONS AND METHODS FOR INCREASING LEAN-TO-FAT MASS RATIO
[patent_app_type] => utility
[patent_app_number] => 17/394649
[patent_app_country] => US
[patent_app_date] => 2021-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14168
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17394649
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/394649 | Compositions and methods for increasing lean-to-fat mass ratio | Aug 4, 2021 | Issued |
Array
(
[id] => 17828380
[patent_doc_number] => 20220265684
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING ULCERATIVE COLITIS
[patent_app_type] => utility
[patent_app_number] => 17/392483
[patent_app_country] => US
[patent_app_date] => 2021-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2661
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17392483
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/392483 | COMPOSITIONS AND METHODS FOR TREATING ULCERATIVE COLITIS | Aug 2, 2021 | Abandoned |
Array
(
[id] => 20578408
[patent_doc_number] => 12570650
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-10
[patent_title] => 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders
[patent_app_type] => utility
[patent_app_number] => 18/019721
[patent_app_country] => US
[patent_app_date] => 2021-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30557
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 242
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019721
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/019721 | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders | Aug 2, 2021 | Issued |
Array
(
[id] => 18994684
[patent_doc_number] => 11911502
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-02-27
[patent_title] => Pharmaceutical compositions and methods of using the same
[patent_app_type] => utility
[patent_app_number] => 17/388703
[patent_app_country] => US
[patent_app_date] => 2021-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 34
[patent_figures_cnt] => 48
[patent_no_of_words] => 61248
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 162
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17388703
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/388703 | Pharmaceutical compositions and methods of using the same | Jul 28, 2021 | Issued |
Array
(
[id] => 17227059
[patent_doc_number] => 20210353615
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF SEROTONERGIC DRUGS
[patent_app_type] => utility
[patent_app_number] => 17/388252
[patent_app_country] => US
[patent_app_date] => 2021-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22070
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17388252
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/388252 | Compositions and methods comprising a combination of serotonergic drugs | Jul 28, 2021 | Issued |
Array
(
[id] => 18389779
[patent_doc_number] => 20230157997
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2023-05-25
[patent_title] => COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/388257
[patent_app_country] => US
[patent_app_date] => 2021-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28974
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17388257
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/388257 | Compositions comprising a serotonergic tryptamine compound | Jul 28, 2021 | Issued |
Array
(
[id] => 18389779
[patent_doc_number] => 20230157997
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2023-05-25
[patent_title] => COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/388257
[patent_app_country] => US
[patent_app_date] => 2021-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28974
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17388257
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/388257 | Compositions comprising a serotonergic tryptamine compound | Jul 28, 2021 | Issued |
Array
(
[id] => 17670872
[patent_doc_number] => 20220184039
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES RELATING THERETO
[patent_app_type] => utility
[patent_app_number] => 17/386138
[patent_app_country] => US
[patent_app_date] => 2021-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31424
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -48
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17386138
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/386138 | Ophthalmic pharmaceutical compositions and uses relating thereto | Jul 26, 2021 | Issued |
Array
(
[id] => 17685747
[patent_doc_number] => 20220193039
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => APPLICATION OF 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES IN ANTIVIRAL THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/615287
[patent_app_country] => US
[patent_app_date] => 2021-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7987
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17615287
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/615287 | APPLICATION OF 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES IN ANTIVIRAL THERAPY | Jul 14, 2021 | Abandoned |
Array
(
[id] => 17355279
[patent_doc_number] => 20220016075
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => METHODS FOR THE TREATMENT OF MYCOBACTERIUM INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/375403
[patent_app_country] => US
[patent_app_date] => 2021-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16332
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17375403
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/375403 | METHODS FOR THE TREATMENT OF MYCOBACTERIUM INFECTIONS | Jul 13, 2021 | Abandoned |